Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Respiratory Complications Associated With COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus Infection Using Wharton's Jelly-Umbilical Cord Mesenchymal Stromal Cells (ProTrans®): Open Phase IB Clinical Trial

NCT04896853 is registered in ClinicalTrials.gov with NextCell Pharma Ab as lead sponsor.

NCT NCT04896853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04896853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Respiratory Complications Associated With COVID-19, Influenza A, Metapneumovirus, Respiratory Syncytial Virus Infection Using Wharton's Jelly-Umbilical Cord Mesenchymal Stromal Cells (ProTrans®): Open Phase IB Clinical Trial
Lead sponsor
NextCell Pharma Ab
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 18, 2021
Completion date
May 31, 2027
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 acute respiratory distress syndrome, influenza a, metapneumovirus pneumonia, respiratory syncytial virus (rsv)